Managing severe cancer pain: The role of transdermal buprenorphine: A systematic review

S. Deandrea, O. Corli, I. Moschetti, Giovanni Apolone

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Pain is a frequent and important symptom in cancer patients. Among the available strong opioids, transdermal buprenorphine has been licensed in Europe since 2002, and results from a few clinical studies suggest that it may be a good alternative to the other oral or transdermal opioids. To assess the best available evidence on its efficacy and safety, we carried out a systematic literature review with the aim of pooling relevant studies. We identified 19 eligible papers describing 12 clinical studies (6 randomized controlled trials and 6 observational prospective studies), including a total of about 5000 cancer patients. Given the poor quality of reports and the heterogeneity of methods and outcomes, pooling was not feasible as the type of data was not appropriate for combining the results statistically. A meta-analysis based on individual data is ongoing in the context of the Cochrane Collaboration. In conclusion, although the narrative appraisal of each study suggests a positive risk benefit profile, well designed and statistically powered controlled clinical trials are needed to confirm this preliminary evidence.

Original languageEnglish
Pages (from-to)707-718
Number of pages12
JournalTherapeutics and Clinical Risk Management
Volume5
Issue number1
Publication statusPublished - 2009

Fingerprint

Buprenorphine
Opioid Analgesics
pain
cancer
Controlled Clinical Trials
Observational Studies
evidence
Meta-Analysis
Neoplasms
Randomized Controlled Trials
Prospective Studies
Safety
narrative
Pain
Cancer Pain
Clinical Studies
literature

Keywords

  • Cancer pain
  • Systematic review
  • Transdermal buprenorphine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Managing severe cancer pain : The role of transdermal buprenorphine: A systematic review. / Deandrea, S.; Corli, O.; Moschetti, I.; Apolone, Giovanni.

In: Therapeutics and Clinical Risk Management, Vol. 5, No. 1, 2009, p. 707-718.

Research output: Contribution to journalArticle

@article{aba02d7ae430468da03049c3957b6b56,
title = "Managing severe cancer pain: The role of transdermal buprenorphine: A systematic review",
abstract = "Pain is a frequent and important symptom in cancer patients. Among the available strong opioids, transdermal buprenorphine has been licensed in Europe since 2002, and results from a few clinical studies suggest that it may be a good alternative to the other oral or transdermal opioids. To assess the best available evidence on its efficacy and safety, we carried out a systematic literature review with the aim of pooling relevant studies. We identified 19 eligible papers describing 12 clinical studies (6 randomized controlled trials and 6 observational prospective studies), including a total of about 5000 cancer patients. Given the poor quality of reports and the heterogeneity of methods and outcomes, pooling was not feasible as the type of data was not appropriate for combining the results statistically. A meta-analysis based on individual data is ongoing in the context of the Cochrane Collaboration. In conclusion, although the narrative appraisal of each study suggests a positive risk benefit profile, well designed and statistically powered controlled clinical trials are needed to confirm this preliminary evidence.",
keywords = "Cancer pain, Systematic review, Transdermal buprenorphine",
author = "S. Deandrea and O. Corli and I. Moschetti and Giovanni Apolone",
year = "2009",
language = "English",
volume = "5",
pages = "707--718",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Managing severe cancer pain

T2 - The role of transdermal buprenorphine: A systematic review

AU - Deandrea, S.

AU - Corli, O.

AU - Moschetti, I.

AU - Apolone, Giovanni

PY - 2009

Y1 - 2009

N2 - Pain is a frequent and important symptom in cancer patients. Among the available strong opioids, transdermal buprenorphine has been licensed in Europe since 2002, and results from a few clinical studies suggest that it may be a good alternative to the other oral or transdermal opioids. To assess the best available evidence on its efficacy and safety, we carried out a systematic literature review with the aim of pooling relevant studies. We identified 19 eligible papers describing 12 clinical studies (6 randomized controlled trials and 6 observational prospective studies), including a total of about 5000 cancer patients. Given the poor quality of reports and the heterogeneity of methods and outcomes, pooling was not feasible as the type of data was not appropriate for combining the results statistically. A meta-analysis based on individual data is ongoing in the context of the Cochrane Collaboration. In conclusion, although the narrative appraisal of each study suggests a positive risk benefit profile, well designed and statistically powered controlled clinical trials are needed to confirm this preliminary evidence.

AB - Pain is a frequent and important symptom in cancer patients. Among the available strong opioids, transdermal buprenorphine has been licensed in Europe since 2002, and results from a few clinical studies suggest that it may be a good alternative to the other oral or transdermal opioids. To assess the best available evidence on its efficacy and safety, we carried out a systematic literature review with the aim of pooling relevant studies. We identified 19 eligible papers describing 12 clinical studies (6 randomized controlled trials and 6 observational prospective studies), including a total of about 5000 cancer patients. Given the poor quality of reports and the heterogeneity of methods and outcomes, pooling was not feasible as the type of data was not appropriate for combining the results statistically. A meta-analysis based on individual data is ongoing in the context of the Cochrane Collaboration. In conclusion, although the narrative appraisal of each study suggests a positive risk benefit profile, well designed and statistically powered controlled clinical trials are needed to confirm this preliminary evidence.

KW - Cancer pain

KW - Systematic review

KW - Transdermal buprenorphine

UR - http://www.scopus.com/inward/record.url?scp=77949471808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949471808&partnerID=8YFLogxK

M3 - Article

C2 - 19774212

AN - SCOPUS:77949471808

VL - 5

SP - 707

EP - 718

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 1

ER -